Publications by authors named "Elena Inzoli"
Article Synopsis
- SETBP1 mutations are associated with various clonal myeloid disorders, but their role in initiating leukemia is uncertain, as they usually occur later in the progression of the disease.
- Researchers created a mouse model with SETBP1 mutations in blood-forming tissue, which resulted in significant changes in cell differentiation and the development of a serious myeloid neoplasm.
- In a study of triple-negative primary myelofibrosis patients, two groups were identified—those with SETBP1 mutations, who experienced more aggressive disease, and those without mutations, suggesting that SETBP1 mutations may act earlier in some clonal disorders than previously thought.
Article Synopsis
- Erythropoiesis-stimulating agents (ESA), particularly biosimilars (B-ESA), show promise in treating anemia in myelofibrosis (MF), although their effectiveness is not fully established.
- A study of 96 MF patients indicated an 80% anemia response rate with B-ESA, where important factors for response included being transfusion-independent and having low ferritin levels at the start of treatment.
- The treatment was generally well-tolerated, with only 2.5% discontinuing due to toxicity, and those who responded to B-ESA had better survival rates compared to non-responders, suggesting the need for further research on its clinical benefits.
TKI discontinuation proved to be safe and feasible in patients with CML with deep and durable molecular responses, introducing an additional treatment goal for these patients beyond overall survival. However, treatment interruption is a safe procedure only with appropriate patient selection and monitoring. Clinical and biological factors associated with better outcomes do not yet offer a precise stratification of patients according to their risk of relapse.
View Article and Find Full Text PDF